Rexoflus® As Novel Potential Therapeutic Option for The Treatment of Gastroesophageal and Laryngopharyngeal Reflux Disease

Background: Gastroesophageal reflux disease (GERD) and laryngopharyngeal reflux disease (LPRD) are two common pathologies with a high diffusion in the world population. Symptoms reduction in GERD and LRPD can be effectively achieved by combining pharmacological treatment with non-pharmacological ones and dietary improvements. REXOFLUS® is a medical device composed of a patented blend of polysaccharides combined with antacid components. It is indicated for the treatment of gastroesophageal and laryngopharyngeal reflux reducing associated symptoms. This study aimed to evaluate the effect of the medical device REXOFLUS® on GERD and LPRD. Aim and Methods: The present observational clinical survey was designed to evaluate the effects of the medical device REXOFLUS® on 51 patients, both as a standalone treatment for GERD and LPRD episodes or in combination with PPI therapy, over the entire duration of treatment, investigating its effectiveness and safety. Results: Rexoflus® treatment after one month reduced the main parameter of reflux diseases according to two different questionnaire used RSI and GIS score. Moreover, the association of Rexoflus® with PPIs showed an improved reduction in the GIS score without showing any side effect. Conclusions: These results represent an optimum starting point and, after a more complete clinical investigation, if the data will be confirmed, it could be possible to consider Rexoflus® as novel therapeutic tool for GERD and LPRD.